ERBB2 and breast carcinoma: However, as a prognostic surrogate for discriminating breast cancer subtypes, the mean expression level of miR-139 is lower in HER2-enriched breast tumors but shows no significant difference in frequency compared to other breast cancer subtypes (Supplementary Figure S2 and Table S2).